Abstract
Five independently evolved classes (α-, β-, γ-, δ-, ζ-) of carbonic anhydrases facilitate the reversible hydration of carbon dioxide to bicarbonate of which the α-class is the most extensively studied. Detailed inhibition studies of the α-class with the two main classes of inhibitors, sulfonamides and metal-complexing anions, revealed many inhibitors that are used as therapeutic agents to prevent and treat many diseases. Recent inhibitor studies of the archaeal β-class (Cab) and the γ-class (Cam) carbonic anhydrases show differences in inhibition response to sulfonamides and metal-complexing anions, when compared to the α-class carbonic anhydrases. In addition, inhibition between Cab and Cam differ. These inhibition patterns are consistent with the idea that although, α-, β-, and γ-class carbonic anhydrases participate in the same two-step isomechanism, diverse active site architecture among these classes predicts variations on the catalytic mechanism. These inhibitor studies of the archaeal β- and γ-class carbonic anhydrases give insight to new applications of current day carbonic anhydrase inhibitors, as well as direct research to develop new compounds that may be specific inhibitors of prokaryotic carbonic anhydrases.
Keywords: glutamine, Pisum sativum, bicarbonate, heterocyclic sulfonamides, Anion Inhibition
Current Topics in Medicinal Chemistry
Title: Inhibition of the Archaeal β-Class (Cab) and γ-Class (Cam) Carbonic Anhydrases
Volume: 7 Issue: 9
Author(s): Sabrina A. Zimmerman, James G. Ferry and Claudiu T. Supuran
Affiliation:
Keywords: glutamine, Pisum sativum, bicarbonate, heterocyclic sulfonamides, Anion Inhibition
Abstract: Five independently evolved classes (α-, β-, γ-, δ-, ζ-) of carbonic anhydrases facilitate the reversible hydration of carbon dioxide to bicarbonate of which the α-class is the most extensively studied. Detailed inhibition studies of the α-class with the two main classes of inhibitors, sulfonamides and metal-complexing anions, revealed many inhibitors that are used as therapeutic agents to prevent and treat many diseases. Recent inhibitor studies of the archaeal β-class (Cab) and the γ-class (Cam) carbonic anhydrases show differences in inhibition response to sulfonamides and metal-complexing anions, when compared to the α-class carbonic anhydrases. In addition, inhibition between Cab and Cam differ. These inhibition patterns are consistent with the idea that although, α-, β-, and γ-class carbonic anhydrases participate in the same two-step isomechanism, diverse active site architecture among these classes predicts variations on the catalytic mechanism. These inhibitor studies of the archaeal β- and γ-class carbonic anhydrases give insight to new applications of current day carbonic anhydrase inhibitors, as well as direct research to develop new compounds that may be specific inhibitors of prokaryotic carbonic anhydrases.
Export Options
About this article
Cite this article as:
Zimmerman A. Sabrina, Ferry G. James and Supuran T. Claudiu, Inhibition of the Archaeal β-Class (Cab) and γ-Class (Cam) Carbonic Anhydrases, Current Topics in Medicinal Chemistry 2007; 7 (9) . https://dx.doi.org/10.2174/156802607780636753
DOI https://dx.doi.org/10.2174/156802607780636753 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis, In silico and Biological Studies of Thiazolyl-2h-chromen-2-one Derivatives as Potent Antitubercular Agents
Current Computer-Aided Drug Design The Evil Axis of Obesity, Inflammation and Type-2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Bacteriophage and Peptidoglycan Degrading Enzymes with Antimicrobial Applications
Recent Patents on Biotechnology Prevalence of HIV Drug Resistance Mutation in the Northern Indian Population After Failure of the First Line Antiretroviral Therapy
Current HIV Research Treatment of Opportunistic Infections Prior to HAART Initiation Does Not Affect Immune Reconstitution in HIV-Infected Patients
Current HIV Research A Method to Prepare Solid Lipid Nanoparticles with Improved Entrapment Efficiency of Hydrophilic Drugs
Current Nanoscience Evolution of the DUT Gene: Horizontal Transfer between Host and Pathogen in all Three Domains of Life
Current Protein & Peptide Science Modulation of Inflammatory Immune Reactions by Low-Dose Ionizing Radiation: Molecular Mechanisms and Clinical Application
Current Medicinal Chemistry Current Nanotechnological Approaches for an Effective Delivery of Bioactive Drug Molecules to Overcome Drug Resistance Tuberculosis
Current Pharmaceutical Design The Spectrum of Cefditoren for Lower Respiratory Tract Infections (LRTIs) in Surabaya
Current Drug Therapy Mechanism(s) Involved in Opioid Drug Abuse Modulation of HAND
Current HIV Research An Updated Review on the Most Common Agents Causing Toxic Optic Neuropathies
Current Pharmaceutical Design DNA Vaccine and the CNS Axonal Regeneration
Current Pharmaceutical Design Implication on the Function of Novel Xn-relE Toxin Structure of Xenorhabdus nematophila Using Homology Modeling
Current Bioinformatics DNA Microarrays - An Armory for Combating Infectious Diseases in the New Century
Infectious Disorders - Drug Targets Biologic Therapies in Primary Sjögren's Syndrome
Current Pharmaceutical Biotechnology Mucosal Vaccines: Where Do We Stand?
Current Topics in Medicinal Chemistry Recent Patents and Advances on Anti - Tuberculosis Drug Delivery and Formulations
Recent Patents on Drug Delivery & Formulation Novel Agents in the Management of Mycobacterium Tuberculosis Disease
Current Medicinal Chemistry p38 Mitogen-Activated Protein Kinase (MAPK) in Rheumatoid Arthritis
Mini-Reviews in Medicinal Chemistry